Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 39

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 39
---
 transaction by a holder
of the number of Ordinary Shares represented by the Depositary Shares for which the warrant is exercisable immediately prior to such fundamental
transaction. In addition, with respect to the Series C Warrants, Series D Warrants and the May 2023 Placement Agent Warrants, in the event
of a fundamental transaction that is (i) an all cash or substantially all cash transaction, (ii) a “Rule 13e-3 transaction”
as defined in Rule 13e-3 under the Exchange Act, or (iii) with certain limited exceptions, a fundamental transaction involving a person
or entity not traded on a national securities exchange or other established trading market, including, but not limited to, the London
Stock Exchange, AIM, The New York Stock Exchange, Inc., The NYSE MKT, The NASDAQ Global Select Market, The NASDAQ Global Market, The NASDAQ
Capital Market, the OTC QX, the OTC QB or the Over-the-Counter Bulletin Board, then the Company or any successor entity will pay at the
holder’s option, exercisable at any time concurrently with or within 30 days after the consummation of the fundamental transaction,
an amount of cash equal to the value of the warrant as determined in accordance with the Black Scholes option pricing model.

| 22 |

Transferability. Each warrant
and all rights thereunder are transferable, in whole or in part, upon surrender of the warrant, together with a written assignment of
the warrant subject to applicable securities laws; provided, however, that the May 2023 Placement Agent Warrants are subject to certain
FINRA transfer restrictions. We do not intend to apply for listing of the warrants on any securities exchange or other trading system.

No Rights as Shareholder Until Exercise. Except
as set forth in the warrants, the holders of the warrants do not have any voting rights, dividends or other rights as a holder of our
capital stock until they exercise the warrants.

Series E Warrants, December 2023 Private Placement Pre-Funded Warrants and December 2023 Underwriter Warrants

The following is a brief summary of
the Series E Warrants, December 2023 Private Placement Pre-Funded Warrants, the December 2023 Underwriter Warrants, issued in connection
with the with December 2023 Private Placement and December 2023 underwritten public offering, and is subject in all respects to the provisions
contained in the applicable warrants, which are filed as exhibits